23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › 10X GENOMICS INC. › 2023-2024

10X GENOMICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and 10X GENOMICS INC.’s Form 8-K, filed June 13, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 347Asset managers, any item
  • 1,572Fund votes
  • June 11, 2024Meeting date

Results at a glance

Meeting of June 11, 2024: 4 items on 10X GENOMICS INC.’s Form 8-K, filed June 13, 2024: 2 approved · 1 passed (calculated) · 1 not approved.

Not approved or not elected

Dissent

No notable dissent beyond the items above.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore 10X GENOMICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by 10X GENOMICS INC.

These tallies are 10X GENOMICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

10X GENOMICS INC. — official shareholder meeting results, meeting held June 11, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Kimberly J. Popovits 198,553,13618,689,301125,755 --11,864,638 91%Passed (calculated)—
2. Ratification of Independent Registered Public Accounting Firm 228,845,897174,119212,814 ---- 99.9%Approved—
3. Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval 112,727,437104,506,389134,366 --11,864,638 51.9%Not approved
A stricter vote than a majority of the votes cast may have applied to this item; the filing does not state it.
—
4. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers 180,775,07036,417,839175,283 --11,864,638 83%Approved—

Source: 10X GENOMICS INC., Form 8-K, filed with the SEC on June 13, 2024 — read the filing on EDGAR.

How asset managers voted at the 10X GENOMICS INC. 2023-2024 meeting

347 asset managers disclosed a vote on at least one 10X GENOMICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Kimberly J. Popovits

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 198,553,136AGAINST: 18,689,301
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: Election of Directors: Election of the one Class II director listed in the accompanying proxy statement, to serve a three-year term expiring at the 2027 annual meeting of stockholders or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal; Kimberly J. Popovits

10X GENOMICS INC.’s own tally for this item (“Elect Director: Kimberly J. Popovits”): 198,553,136 for, 18,689,301 against, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 40,144,209 for, 7,034,283 against.

FORAGAINST
FOR: 40,144,209AGAINST: 7,034,283
Largest asset managers voting on “Election of Directors: Election of the one Class II director listed in the accompanying proxy statement, to se” at 10X GENOMICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity13,458,1181,519,256 00Mixed
Vanguard10,384,9890 00For
ARK ETF Trust6,004,3250 00For
T. Rowe Price03,881,668 00Against
BlackRock1,706,9150 00For
Morgan Stanley1,614,2120 00For
Brown Capital Management Mutual Funds1,249,5110 00For
Charles Schwab940,4600 00For
Capital Group793,3000 00For
TOUCHSTONE FUNDS GROUP TRUST691,1050 00For
FRANKLIN STRATEGIC SERIES648,0000 00For
Columbia Threadneedle418,1410 00For
BNY Mellon0408,754 00Against
ALGER FUNDS0360,492 00Against
Transamerica259,37537,809 00Mixed
Voya287,9870 00For
TIAA0249,365 00Against
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)240,0000 00For
Equitable149,46547,828 00Mixed
Putnam191,6560 00For
AMERICAN BEACON FUNDS158,2140 00For
Jackson National62,55980,998 00Mixed
Russell Investments138,5990 00For
Brighthouse110,63016,376 00Mixed
John Hancock0117,462 00Against

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to…

Official resultCORPORATE GOVERNANCEReported outcome: Not approved

Combines 5 wordings of this item as funds reported it.

51.9% Not approved · of votes cast

FOR 51.9%AGAINST
FOR: 112,727,437AGAINST: 104,506,389
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: A vote to approve an amendment to our amended and restated bylaws such that the bylaws may be amended by our board of directors without requiring stockholder approval;

10X GENOMICS INC.’s own tally for this item (“3. Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval”): 112,727,437 for, 104,506,389 against — failed, per its Form 8-K filed June 13, 2024 (Item 5.07). This item required more than a simple majority of votes cast — see the filing.

Reported outcome: Not approved, in the filing’s own words: “Proposal 3 - Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval The Company's stockholders did not approve a proposed amendment to the Company'…”
A stricter vote than a majority of the votes cast may have applied to this item; the filing does not state it.
Support: 51.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 11,455,634 for, 35,722,858 against.

FORAGAINST
FOR: 11,455,634AGAINST: 35,722,858
Largest asset managers voting on “A vote to approve an amendment to our amended and restated bylaws such that the bylaws may be amended by our b” at 10X GENOMICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity014,977,374 00Against
Vanguard1,436,8788,948,111 00Mixed
ARK ETF Trust6,004,3250 00For
T. Rowe Price03,881,668 00Against
BlackRock01,706,915 00Against
Morgan Stanley01,614,212 00Against
Brown Capital Management Mutual Funds1,249,5110 00For
Charles Schwab940,4600 00For
Capital Group0793,300 00Against
TOUCHSTONE FUNDS GROUP TRUST0691,105 00Against
FRANKLIN STRATEGIC SERIES648,0000 00For
Columbia Threadneedle0418,141 00Against
BNY Mellon0408,754 00Against
ALGER FUNDS0360,492 00Against
Transamerica0297,184 00Against
Voya0287,987 00Against
TIAA249,3650 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)0240,000 00Against
Equitable0197,293 00Against
Putnam191,6560 00For
AMERICAN BEACON FUNDS158,2140 00For
Jackson National10,633132,924 00Mixed
Russell Investments138,5990 00For
Brighthouse0127,006 00Against
John Hancock0117,462 00Against

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 11 wordings of this item as funds reported it.

83% Approved · of votes cast

FOR 83%AGAINST
FOR: 180,775,070AGAINST: 36,417,839

Prior year: 82.8% for (June 14, 2023 meeting) ▲ 0.4 pts

Details: description as filed, official tally, votes by 346 asset managers

Description as filed by funds: A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and

10X GENOMICS INC.’s own tally for this item (“4. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers”): 180,775,070 for, 36,417,839 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy state…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 74 asset managers voting on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and” at 10X GENOMICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity13,406,3581,571,016 00Mixed
Vanguard8,948,1111,436,878 00Mixed
ARK ETF Trust6,004,3250 00For
T. Rowe Price1,442,1952,439,473 00Mixed
BlackRock01,706,915 00Against
Morgan Stanley1,608,4065,806 00For
Brown Capital Management Mutual Funds01,249,511 00Against
Charles Schwab0940,460 00Against
Capital Group0793,300 00Against
TOUCHSTONE FUNDS GROUP TRUST691,1050 00For
FRANKLIN STRATEGIC SERIES0648,000 00Against
Columbia Threadneedle418,1410 00For
BNY Mellon23,778384,976 00Mixed
ALGER FUNDS0360,492 00Against
Transamerica259,37537,809 00Mixed
Voya287,9870 00For
TIAA0249,365 00Against
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)0240,000 00Against
Equitable142,98754,306 00Mixed
Putnam0191,656 00Against
AMERICAN BEACON FUNDS158,2140 00For
Jackson National66,80176,756 00Mixed
Russell Investments0138,599 00Against
Brighthouse110,63016,376 00Mixed
John Hancock0117,462 00Against

Fund voting reports, all 74 managers: 33,736,240 for, 13,423,075 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 291 asset managers voting on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and” at 10X GENOMICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity16,988,1310 00For
T. Rowe Price2,088,7093,278,557 00Mixed
BAILLIE GIFFORD & CO LTD03,850,099 00Against
Nikko Asset Management Americas, Inc.03,816,669 00Against
Morgan Stanley3,465,1950 00For
BlackRock60,8772,541,148 00Against
SANDS CAPITAL MANAGEMENT, LLC2,288,0510 00For
BAILLIE GIFFORD OVERSEAS LTD01,889,073 00Against
GEODE CAPITAL MANAGEMENT, LLC01,635,730 00Against
BROWN CAPITAL MANAGEMENT LLC01,598,610 00Against
UBS01,354,213 00Against
RTW INVESTMENTS, LP1,208,0660 00For
GENERATION INVESTMENT MANAGEMENT LLP0975,905 00Against
Charles Schwab0944,952 00Against
FRANKLIN ADVISERS INC0823,336 00Against
Putnam0816,540 00Against
Capital Group43793,300 00Against
Freshford Capital Management, LLC781,9070 00For
State Street721,94643,436 00Mixed
NEW YORK STATE COMMON RETIREMENT FUND0560,457 00Against
Northern Trust532,82764 00For
Meritech Capital Associates V L.L.C.00 494,2360Abstain
Sands Capital Ventures, LLC481,7700 00For
BOSTON MANAGEMENT & RESEARCH0467,079 00Against
Newton Investment Management North America, LLC0456,140 00Against

Institutional-manager reports, all 291 managers: 30,220,671 for, 31,993,744 against, 30,065 withheld, 503,687 abstained, 9,803 not voted, 46 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 228,845,897AGAINST: 174,119

Prior year: 100.0% for (June 14, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

10X GENOMICS INC.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 228,845,897 for, 174,119 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 47,178,492 for.

FOR
FOR: 47,178,492
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at 10X GENOMICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity14,977,3740 00For
Vanguard10,384,9890 00For
ARK ETF Trust6,004,3250 00For
T. Rowe Price3,881,6680 00For
BlackRock1,706,9150 00For
Morgan Stanley1,614,2120 00For
Brown Capital Management Mutual Funds1,249,5110 00For
Charles Schwab940,4600 00For
Capital Group793,3000 00For
TOUCHSTONE FUNDS GROUP TRUST691,1050 00For
FRANKLIN STRATEGIC SERIES648,0000 00For
Columbia Threadneedle418,1410 00For
BNY Mellon408,7540 00For
ALGER FUNDS360,4920 00For
Transamerica297,1840 00For
Voya287,9870 00For
TIAA249,3650 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)240,0000 00For
Equitable197,2930 00For
Putnam191,6560 00For
AMERICAN BEACON FUNDS158,2140 00For
Jackson National143,5570 00For
Russell Investments138,5990 00For
Brighthouse127,0060 00For
John Hancock117,4620 00For

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Largest 10X GENOMICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 119,095,362 shares outstanding at the time of that meeting.

Fund voting reports: top 10X GENOMICS INC. shareholders by shares voted on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 12.58%
2Vanguard 8.72%
3ARK ETF Trust 5.04%
4T. Rowe Price 3.26%
5BlackRock 1.43%
6Morgan Stanley 1.36%
7Brown Capital Management Mutual Funds 1.05%
8Charles Schwab 0.79%
9Capital Group 0.67%
10TOUCHSTONE FUNDS GROUP TRUST 0.58%
Institutional-manager reports: top 10X GENOMICS INC. shareholders by shares voted on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 14.26%
2T. Rowe Price 4.51%
3BAILLIE GIFFORD & CO LTD 3.23%
4Nikko Asset Management Americas, Inc. 3.20%
5Morgan Stanley 2.91%
6BlackRock 2.18%
7SANDS CAPITAL MANAGEMENT, LLC 1.92%
8BAILLIE GIFFORD OVERSEAS LTD 1.59%
9GEODE CAPITAL MANAGEMENT, LLC 1.37%
10BROWN CAPITAL MANAGEMENT LLC 1.34%

Reported 10X GENOMICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

10X GENOMICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group13,274,332 11.15%Form 13F, quarter ended March 31, 2024
BlackRock9,460,109 7.94%Form 13F, quarter ended March 31, 2024
FMR (Fidelity)8,458,001 7.10%Form 13F, quarter ended March 31, 2024
T. Rowe Price3,657,227 3.07%Form 13F, quarter ended March 31, 2024
Morgan Stanley2,817,242 2.37%Form 13F, quarter ended March 31, 2024
Goldman Sachs2,675,327 2.25%Form 13F, quarter ended March 31, 2024
Geode Capital1,643,153 1.38%Form 13F, quarter ended March 31, 2024
State Street1,585,702 1.33%Form 13F, quarter ended March 31, 2024
Millennium Management1,162,428 0.98%Form 13F, quarter ended March 31, 2024
JPMorgan Chase1,073,865 0.90%Form 13F, quarter ended March 31, 2024

Percentages above are of 119,095,362 shares outstanding, as reported by 10X GENOMICS INC. on its Form 10-K dated December 31, 2023 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At 10X GENOMICS INC.'s shareholder meeting held June 11, 2024, in the 2023-2024 proxy season, 347 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,572 separate fund positions. On the most widely held item on that ballot — A vote to approve, on a non-binding, advisory basis, the compensation of our named executive… — 10X GENOMICS INC.'s filing reports the proposal as approved, with 83% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 10X GENOMICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10X GENOMICS INC.’s 10-K dated December 31, 2023. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

10X GENOMICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “10X GENOMICS (TXG) 2024 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/10x-genomics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.